Early Phase I Study of a <sup>99m</sup>Tc-Labeled Anti–Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non–Small Cell Lung Cancer

Yan Xing(Shanghai First People's Hospital), Jinhua Zhao(Shanghai First People's Hospital)
Journal of Nuclear Medicine
February 22, 2019
Cited by 162


Related Papers